ChunLab Inc
CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company's platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson's diseases… Read more
ChunLab Inc (311690) - Net Assets
Latest net assets as of September 2025: ₩59.16 Billion KRW
Based on the latest financial reports, ChunLab Inc (311690) has net assets worth ₩59.16 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩76.34 Billion) and total liabilities (₩17.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩59.16 Billion |
| % of Total Assets | 77.5% |
| Annual Growth Rate | 28.88% |
| 5-Year Change | 125.49% |
| 10-Year Change | N/A |
| Growth Volatility | 81.17 |
ChunLab Inc - Net Assets Trend (2017–2024)
This chart illustrates how ChunLab Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ChunLab Inc (2017–2024)
The table below shows the annual net assets of ChunLab Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩77.76 Billion | +8.76% |
| 2023-12-31 | ₩71.50 Billion | +43.98% |
| 2022-12-31 | ₩49.66 Billion | -43.48% |
| 2021-12-31 | ₩87.85 Billion | +154.76% |
| 2020-12-31 | ₩34.48 Billion | +11.76% |
| 2019-12-31 | ₩30.85 Billion | +186.29% |
| 2018-12-31 | ₩10.78 Billion | -18.12% |
| 2017-12-31 | ₩13.16 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ChunLab Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11411762804000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩6.53 Billion | 8.40% |
| Other Components | ₩190.29 Billion | 244.73% |
| Total Equity | ₩77.76 Billion | 100.00% |
ChunLab Inc Competitors by Market Cap
The table below lists competitors of ChunLab Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bangkok Ranch PCL
BK:BR
|
$25.27 Million |
|
Société des Chemins de Fer et Tramways du Var et du Gard
PA:MLCVG
|
$25.27 Million |
|
Jakarta Int Hotels & Dev
JK:JIHD
|
$25.27 Million |
|
Hankuk Steel Wire Co. Ltd
KQ:025550
|
$25.28 Million |
|
Lumi Gruppen AS
OL:LUMI
|
$25.24 Million |
|
New Hoong Fatt Holdings Bhd
KLSE:7060
|
$25.23 Million |
|
Momentum Metropolitan Holdings Ltd
JSE:MTM
|
$25.23 Million |
|
Blue Star Helium Ltd
PINK:BSNLF
|
$25.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ChunLab Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 71,495,691,640 to 77,756,531,690, a change of 6,260,840,050 (8.8%).
- Net loss of 32,837,724,110 reduced equity.
- Share repurchases of 39,969,769,140 reduced equity.
- New share issuances of 39,969,769,140 increased equity.
- Other factors increased equity by 39,098,564,160.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-32.84 Billion | -42.23% |
| Share Repurchases | ₩39.97 Billion | -51.4% |
| Share Issuances | ₩39.97 Billion | +51.4% |
| Other Changes | ₩39.10 Billion | +50.28% |
| Total Change | ₩- | 8.76% |
Book Value vs Market Value Analysis
This analysis compares ChunLab Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.00x to 1.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩4099.92 | ₩8200.00 | x |
| 2018-12-31 | ₩3347.98 | ₩8200.00 | x |
| 2019-12-31 | ₩8100.56 | ₩8200.00 | x |
| 2020-12-31 | ₩8859.45 | ₩8200.00 | x |
| 2021-12-31 | ₩12836.15 | ₩8200.00 | x |
| 2022-12-31 | ₩8446.71 | ₩8200.00 | x |
| 2023-12-31 | ₩7845.89 | ₩8200.00 | x |
| 2024-12-31 | ₩5951.30 | ₩8200.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ChunLab Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -947.28%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.28x
- Recent ROE (-42.23%) is below the historical average (-31.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -17.95% | -64.34% | 0.25x | 1.14x | ₩-3.68 Billion |
| 2018 | -29.09% | -79.89% | 0.31x | 1.19x | ₩-4.21 Billion |
| 2019 | -14.08% | -90.85% | 0.14x | 1.09x | ₩-7.43 Billion |
| 2020 | -25.41% | -164.97% | 0.07x | 2.13x | ₩-12.21 Billion |
| 2021 | -21.94% | -441.72% | 0.04x | 1.32x | ₩-28.06 Billion |
| 2022 | -70.31% | -856.84% | 0.04x | 1.84x | ₩-39.88 Billion |
| 2023 | -32.05% | -410.99% | 0.06x | 1.27x | ₩-30.06 Billion |
| 2024 | -42.23% | -947.28% | 0.03x | 1.28x | ₩-40.61 Billion |
Industry Comparison
This section compares ChunLab Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ChunLab Inc (311690) | ₩59.16 Billion | -17.95% | 0.29x | $25.25 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |